Overactive Bladder Pipeline Report, 2024 Updates : In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Astellas Pharma Inc., Laborie, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva P

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Overactive Bladder pipeline constitutes 15+ key companies continuously working towards developing 15+ Overactive Bladder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Overactive Bladder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.

The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Overactive Bladder Pipeline Report:
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years.
• Overactive Bladder companies working in the treatment market are Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others, are developing therapies for the Overactive Bladder treatment
• Emerging Overactive Bladder therapies in the different phases of clinical trials are- ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others are expected to have a significant impact on the Overactive Bladder market in the coming years.
• In November 2023, Avation Medical has disclosed encouraging outcomes from the multi-center trial of Vivally, its medical device aimed at addressing overactive bladder (OAB) syndrome. The FREEOAB multi-center study involved 96 OAB patients. Findings indicated notable decreases in daily void, incontinence, and urgency episodes at the 12-week mark, leading to an improved quality of life. Furthermore, these favorable effects endured over the long term, with ongoing enhancements in diary parameters noted at the 12-month follow-up.
• In July 2023, GEMTESA (vibegron) is an oral medication designed to address overactive bladder (OAB) symptoms, including urge urinary incontinence (UUI), urgency, and urinary frequency in adults. It comes in the form of a once-daily, oval, light green, film-coated tablet with a strength of 75mg. Initially developed by Merck, a US-based pharmaceutical company, GEMTESA was later licensed to Japanese company KYORIN Pharmaceutical in July 2014 for further development in Japan and other Asian regions.
• In May 2023, BlueWind Medical, Ltd., the creator of an innovative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), has unveiled findings from the OASIS pivotal trial assessing the safety and effectiveness of the BlueWind System in OAB treatment. These results were presented during the late-breaking session (LBA01-05) at the American Urological Association (AUA) 2023 Annual Meeting in Chicago.
• In March 2023, MSN Laboratories released Fesobig, the generic alternative to Fesoterodine Fumarate, which serves as a primary pharmacological choice for managing Overactive Bladder (OAB) symptoms.
• In January 2023, Alembic Pharmaceuticals Limited obtained approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) concerning Fesoterodine Fumarate tablets, intended for the treatment of Overactive Bladder (OAB) in adults.

Overactive Bladder Overview
Overactive bladder (OAB) is a medical condition characterized by a sudden, uncontrollable urge to urinate, often accompanied by frequency of urination and sometimes urinary incontinence (the involuntary loss of urine). People with OAB may experience a frequent and urgent need to urinate, including waking up multiple times during the night to urinate (nocturia). OAB occurs due to involuntary contractions of the bladder muscles, which can be caused by various factors such as nerve damage, bladder inflammation, or other underlying health conditions.

Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:
• ARD-380: Aardvark Therapeutics
• URB937: Exxel Pharma
• Botulax: Hugel
• IMB-115: Imbrium Therapeutics
• TAC-302: Taiho Pharmaceutical
• URO-902: Sumitovant Biopharma
• DA-8010: Dong-A ST

Overactive Bladder Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Overactive Bladder Molecule Type
Overactive Bladder Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Overactive Bladder Pipeline Therapeutics Assessment
• Overactive Bladder Assessment by Product Type
• Overactive Bladder By Stage and Product Type
• Overactive Bladder Assessment by Route of Administration
• Overactive Bladder By Stage and Route of Administration
• Overactive Bladder Assessment by Molecule Type
• Overactive Bladder by Stage and Molecule Type

DelveInsight's Overactive Bladder Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the emerging Overactive Bladder therapies
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Overactive Bladder Therapeutics Market include:
Key companies developing therapies for Overactive Bladder are - Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma, AbbVie Inc, Allergan, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical, and others.

Overactive Bladder Pipeline Analysis:
The Overactive Bladder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
• Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Overactive Bladder drugs and therapies
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Overactive Bladder Pipeline Market Drivers
• Prevalence of urinary incontinence, approval of generics, growth in the number of product launches are some of the important factors that are fueling the Overactive Bladder Market.

Overactive Bladder Pipeline Market Barriers
• However, lack of diagnosis and information about OAB, side effects associated with the current treatment options and other factors are creating obstacles in the Overactive Bladder Market growth.

Scope of Overactive Bladder Pipeline Drug Insight
• Coverage: Global
• Key Overactive Bladder Companies: Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others
• Key Overactive Bladder Therapies: ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others
• Overactive Bladder Therapeutic Assessment: Overactive Bladder current marketed and Overactive Bladder emerging therapies
• Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers

Request for Sample PDF Report for Overactive Bladder Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Overactive Bladder Report Introduction
2. Overactive Bladder Executive Summary
3. Overactive Bladder Overview
4. Overactive Bladder- Analytical Perspective In-depth Commercial Assessment
5. Overactive Bladder Pipeline Therapeutics
6. Overactive Bladder Late Stage Products (Phase II/III)
7. Overactive Bladder Mid Stage Products (Phase II)
8. Overactive Bladder Early Stage Products (Phase I)
9. Overactive Bladder Preclinical Stage Products
10. Overactive Bladder Therapeutics Assessment
11. Overactive Bladder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Overactive Bladder Key Companies
14. Overactive Bladder Key Products
15. Overactive Bladder Unmet Needs
16 . Overactive Bladder Market Drivers and Barriers
17. Overactive Bladder Future Perspectives and Conclusion
18. Overactive Bladder Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Overactive Bladder Market https://www.delveinsight.com/report-store/overactive-bladder-oab-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Overactive Bladder Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Overactive Bladder Epidemiology https://www.delveinsight.com/report-store/overactive-bladder-oab-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Overactive Bladder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.